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ABSTRACT
AIM: Colorectal cancer is one of the most common cancers, and second-leading cause of cancer-related 
death, in New Zealand. The PIPER (Presentations, Investigations, Pathways, Evaluation, Rx [treatment]) 
project was undertaken to compare presentation, investigations, management and outcomes by rurality, 
ethnicity and deprivation. This paper reports the methods of the project, a comparison of PIPER patient 
diagnoses to the New Zealand Cancer Registry (NZCR) data, and the characteristics of the PIPER cohort. 
METHOD: National, retrospective cohort review of secondary care medical records (public and private) 
of all cases of ICD-10-AM C18-C20 on the NZCR in the calendar years 2007 and 2008 (main cohort) and 
an extended sample of Māori and Pacific cases, and non-Māori non-Pacific controls in 2006 and 2009 
(extended cohort). 
RESULTS: Of the 6,387 patients identified from the NZCR 5,610 (88%) were eligible for PIPER. Reasons 
for exclusion were non-adenocarcinoma histology (3%) and non-colorectal primary (2%). Data were 
collected on 3,695 patients with colon cancer, 1,385 with rectal cancer and 466 with cancer of the recto 
sigmoid junction. 
CONCLUSIONS: The PIPER Project has generated comprehensive population level data detailing the 
diagnosis and management of colorectal adenocarcinoma in New Zealand. This will be used to assess the 
care provided to patients, and the impact of variations in care occurring between patient groups. 
Colorectal cancer (CRC) is the second most common cancer in New Zealand (with 3,016 new cases in 2012) and 
the second-leading cause of cancer-related 
death.1 Australia and New Zealand have 
similar incidence rates; the highest record-
ed worldwide.2 Multiple studies, however, 
suggest survival post-CRC diagnosis is lower 
in New Zealand.3–7 Differences in surviv-
al are likely due to both diagnostic and 
treatment factors.3,7 Identification of these 
factors requires detailed investigation of the 
access to, and quality of, care for patients 
with CRC in New Zealand. 
Professional guidelines relating to the 
optimal management of CRC exist, but 
there are no mandated minimum quality 
standards for delivery of CRC care in New 
Zealand. Previous attempts at comparing 
outcomes, for example via the Colorectal 
Surgical Society of Australia and New 
Zealand audit are limited by incomplete 
population coverage. A National Cancer 
Tumour Standards work programme is 
underway, but—at the time of writing—
standards remain provisional.8 Audits 
undertaken to date against these provi-
sional standards are not uniform 
nationally, are not mandated, are not 
reported centrally, and results have not 
been published.
Disparities in survival post-CRC diag-
nosis are known to exist between groups 
of patients based on rurality, ethnicity and 
socioeconomic status.9–14 Although CRC 
incidence is lower in rural areas and among 
Māori, once diagnosed, these groups are 
more likely to die of the disease compared 
to urban and non-Māori groups.9–11 These 
disparities are not fully explained by 
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differences in stage at diagnosis. Some 
residual confounding is likely because stage 
at diagnosis is an imperfect measure of 
disease status. It is also possible, however, 
that variation in care post diagnosis is 
affecting survival outcomes. Reasons for 
poorer survival for Māori with colon cancer 
have been explored; several differences in 
quality of care indicators were found that 
were not explained by measured disease 
variables (such as stage at diagnosis) or 
patient characteristics.11 
Pacific peoples also have substantially 
lower incidence rates of CRC, however 
estimates of survival are quite unstable 
due to small numbers; further research 
into the care received by Pacific patients, 
and their outcomes is needed.12 Depri-
vation status and household income have 
also been suggested to adversely affect 
cancer outcomes in CRC patients in New 
Zealand,13,14 over and above the influence of 
disease stage at diagnosis and ethnicity.14 
Given the high incidence and with-
in-population disparities in outcome, we 
hypothesised that health service factors 
relating to CRC treatment, as well as patient 
and disease characteristics, were likely to 
negatively impact on outcome. The objec-
tives of the PIPER Project (Presentations, 
Investigations, Pathways, Evaluation, Rx 
[treatment]) were: 
(i) to describe the patterns of presentation 
to secondary care, diagnosis, staging, 
treatment, follow-up and survival
(ii) to compare these patterns according to 
rurality, ethnicity and deprivation
(iii) to investigate the relationship 
between these factors and outcome (cause 
specific and overall survival).15 
The PIPER Project is a national, retro-
spective cohort study including all patients 
diagnosed in New Zealand with colorectal 
adenocarcinoma in 2007 and 2008, along 
with an extended cohort (2006 and 2009) 
for analysing patterns of care for Māori 
and Pacific patients. The project is the 
largest of its kind conducted in New 
Zealand to date and utilises data collected 
directly from medical records, including 
from the private sector. 
In this paper we report the methods of 
the PIPER Project, compare the CRC diag-
noses recorded by PIPER to those on the 
New Zealand Cancer Registry (NZCR), and 
describe the characteristics of the patients 
included in the PIPER cohort.
Methods
Study population: All registrations for CRC 
(ICD-10-AM codes C18-C20) in 2006–2009 
were provided by the NZCR16 in a data set 
extracted on 17 May 2012. The NZCR is 
the central repository for all new cancer 
diagnoses (excluding non-melanoma skin 
cancers) that occur in New Zealand, as 
mandated by the Cancer Registry Act 1993.16 
In New Zealand, all patients are allocated 
a unique health system identifier, known 
as the National Health Index (NHI); this 
was used to link people across different 
health-related data sets such as the registry, 
the mortality collection and medical 
records.17
Two cohorts of patients were selected: (i) 
Main cohort: patients diagnosed between 1 
January 2007 and 31 December 2008. This 
period was chosen to be recent enough to 
be relevant to current resource planning 
(given the relatively minor changes in 
management since that time) and provide 
sufficient follow-up time (6–7 years); 
(ii) Extended cohort: this comprised all 
participants in the main cohort as well 
as all Māori and Pacific patients diag-
nosed between 1 January 2006 and 31 Dec 
2006, and 1 Jan 2009 and 31 Dec 2009, to 
provide greater numbers of Māori and 
Pacific patients for subsequent analyses. To 
obtain comparative data over the extended 
time frame we added a stratified random 
sample of non-Māori non-Pacific (nMnP) 
patients also diagnosed in 2006 and 2009. 
The stratification factors were year of 
diagnosis (2006, 2009) and cancer centre 
region (cancer services are delivered 
via six regions: Auckland, Waikato, 
MidCentral, Capital and Coast, Canterbury, 
and Southern District Health Boards); the 
number of nMnP patients selected matched 
the total numbers of eligible Māori and 
Pacific patients in each stratum.
We included all patients whose diag-
nosis of adenocarcinoma of the colon or 
rectum was confirmed by either histology, 
radiology or visualisation of tumour (during 
colonoscopy, sigmoidoscopy or surgery). 
Exclusion criteria were: date of diagnosis 
outside 2007–2008 for patients in the main 
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cohort, and outside 2006 and 2009 for the 
extended cohort; patients with recurrent 
disease (this included recurrent tumour at 
the site of a previous tumour, at the anasto-
mosis following previous surgical resection 
of a CRC, or new metastatic disease on the 
background of a previous CRC tumour); 
patients who presented, were diagnosed, or 
received treatment for their primary CRC 
outside New Zealand; and patients who 
were not residents of New Zealand at the 
time of diagnosis. Cases were checked for 
eligibility by review of public and private 
secondary care clinical records. We defined 
date of diagnosis as the date of the first 
pathological report confirming CRC (where 
pathology was available). This date is often 
later than the date recorded on the NZCR, 
creating some shift in cohorts between NZCR 
diagnosis date and PIPER diagnosis date. The 
scope of the project did not include going 
back through NZCR late 2006 diagnoses to 
check if these would have fallen in the 2007 
cohort as per the PIPER definition. 
Data sources: Data were obtained from 
three main sources: i) retrospective review 
of patients’ clinical records (from both 
public and private sectors) from the first 
presentation to hospital care resulting in 
the diagnosis of CRC until the time of case-
review; ii) the national databases of hospital 
discharge diagnoses (National Minimum 
Dataset, NMDS) and mortality (Mortality 
Collection); iii) national data used to derive 
New Zealand Deprivation Index (a measure 
of deprivation based on regularly collected 
National census data)18 and rurality for 
meshblocks of residence, and the GPS coor-
dinates of meshblock centroids. A meshblock 
is a New Zealand-wide system of identi-
fying geographical units, and is the smallest 
geographical unit for which Statistics New 
Zealand collects and provides statistical 
data.19 National database data were merged 
with the clinical data using NHI numbers.
Demographic characteristics: Date of 
birth, gender and ethnicity were deter-
mined from NZCR data. Ethnicity fields on 
the NZCR are continually updated based 
on hospital and mortality data to improve 
accuracy16 with a prioritisation process 
allowing for multiple ethnic affiliations to 
be recorded, with priority ordering to Māori 
followed by Pacific groups, Asian groups, 
other groups and New Zealand European.20 
Ethnicity data from hospitalisation events 
are self-determined from patients or their 
families using a standard question allowing 
multiple categories of ethnicity.20 Data on all 
hospital discharge diagnoses were obtained 
from the NMDS from five years pre-di-
agnosis to estimate baseline comorbidity 
levels. Previously validated ICD-10 codes 
were used to identify these conditions.21
Rurality was assessed for each patient 
according to their residential address at the 
time of diagnosis. A Statistics New Zealand 
2011 meshblock was assigned to each of 
the addresses using QAS Batch software by 
Experian™. This was then mapped to 2006 
meshblocks, the closest to our main cohort. 
We used the Statistics New Zealand urban/
rural profile classification system to obtain 
a rurality classification. This assigns mesh-
blocks to one of three urban and four rural 
categories based on the dependence of the 
meshblock on a main urban area (assessed 
by comparing residential and employment 
addresses).22 In our main analyses we 
grouped the seven categories into two cate-
gories, urban and rural, as recommended 
by the National Health Committee: rural = 
rural areas with moderate urban influence, 
rural areas with low urban influence, 
highly remote/rural areas and independent 
urban communities; non-rural = main 
urban areas, satellite urban communities 
and rural areas with high urban influence.23 
Centroid coordinates were also assigned 
to each meshblock to calculate a measure 
of travel distance to the diagnostic or 
treatment centre. 
A deprivation score was assigned to each 
patient using the NZDep 2006 Index of 
Deprivation, which provides an area-based 
measure of deprivation for each meshblock 
(derived from New Zealand Census data) 
in deciles based on census variables such 
as financial benefit receipt, earning under 
an income threshold, housing tenure, and 
access to car or phone (1=lowest level of 
deprivation and 9=highest level of depri-
vation).18 The NZDep score was assigned 
to each of the patients’ addresses. Data 
presented in this paper uses the rurality 
category and the NZDep score of the 
address recorded for the patient at the time 
of diagnosis. 
Key Performance indicators (KPIs) for 
measuring quality of care: PIPER’s inves-
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tigators and advisory group members 
consisted of individuals with expertise 
in colorectal surgery, medical oncology, 
radiation oncology, Māori health, Pacific 
health, general practice, rural health, 
patients’ perspectives, biostatistics, health 
management, and clinical data collection. 
We identified a list of KPIs based on 
national and international guidelines.24–28 
A list of the data fields required to assess 
these KPIs was developed and piloted, with 
amendments based on availability and 
completeness of data in hospital notes. Data 
collected included patient demographics 
and co-morbidity, method of referral to 
secondary care, First Specialist Assessment 
(FSA), diagnosis, disease characteristics, 
cancer treatment, timelines, follow-up and 
outcome. A full list of data fields collected is 
provided in (Table 1). 
The following fields were deemed unable 
to be collected during the pilot phase, 
due to a high proportion of missing data: 
baseline aspirin/ NSAID use; age of family 
member diagnosed with cancer (medical 
history); pre-chemotherapy height and 
weight; Eastern Cooperative Oncology 
Group (ECOG) performance status; planned 
duration of chemotherapy; response to 
chemotherapy; stage of disease as recorded 
by medical or radiation oncologist.
Outcomes: Data on disease outcomes 
were collected in the clinical record review 
(Table 1). Data on all hospital discharge 
diagnoses (adverse events) from 1 Jan 2001 
(pre-CRC diagnosis) to post-CRC diagnosis 
until 10 April 2014 (date of extraction) 
were obtained from the National Minimum 
Dataset. Mortality data were obtained from 
the Mortality Collection, which provided 
mortality data to 28 Feb 2015 and coded 
cause of death until 31 Dec 2013. 
Data collection: Clinical data were 
extracted from local hospital databases, 
patient electronic records and hard copy 
medical files. Data for patients treated 
in the private sector were collected from 
private clinicians’ medical records following 
the clinician’s written agreement. Data 
collection for each patient was carried out 
by regional data managers, trained in the 
use of PIPER’s standardised data collection 
manual. Data managers reviewed potential 
cases for eligibility based on the DHB of 
domicile of the patient as recorded on the 
initial NZCR data set. If no information 
or no relevant (eg, cancer-related) infor-
mation was found at the centre closest to 
the patient’s domicile, a check against the 
national database of hospital admissions 
was undertaken to identify patients who 
may have been diagnosed or treated in 
regions other than their DHB of domicile as 
recorded by the NZCR. Data were extracted 
and either written onto a case report form 
and then entered into the project database, 
or entered directly into the project database. 
In each field the “Unknown” category refers 
to fields that were still unknown after all 
available information for the patient had 
been reviewed. 
The PIPER Project database: A central 
Microsoft Access database was designed, 
developed and maintained by Cancer 
Trials New Zealand. This is housed on the 
University of Auckland secure server and 
is accessible only by secure log-on and 
password. Data managers at external sites 
accessed the database via remote sessions 
to the host server, which required indi-
vidual user log on and password. Data 
sourced from national databases were 
also stored in a Microsoft Access database 
housed on the secure server. Data were 
anonymised for analysis.
Quality control: The database was 
developed using the fundamentals of good 
database design, including branch logic, 
limited field entry and dropdown lists to 
attain quality data entry. Reports were 
produced to ascertain completeness of 
data collection for individual patients. The 
following steps were taken to maintain 
consistent data extraction across the 
various centres: data managers underwent 
induction by the project manager; a data 
collection manual was developed which 
contained a definition for each data field 
and suggested documents to obtain the data 
from, listed in order of priority or relevance 
if more than one source was identified; the 
project manager made two visits to each 
site to conduct duplicate data extraction 
with review and feedback of any issues; 
queries on clinical data were reviewed by 
the project manager or clinical investigators 
and discussed at monthly data manager 
teleconferences. Checks were carried out 
across all sources of data to identify incon-
gruities, including date order checks and 
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Table 1: Summary of the PIPER Project Data Fields.
Demographics Treatment
Patient ID
Date of Birth
Gender
Ethnicity
Not for active treatment
Date of decision not for active treatment
First treatment received
Surgical referral
Surgical FSA 
Surgical FSA date
Primary resected
Other cancer-related surgical procedure
Surgical procedure
Indication of surgery
Date of surgery
Date of discharge
Length of stay
Main surgical procedure 
Return to theatre
Anastomotic leak
30 day mortality
90 day mortality
Myocardial Infarction (MI)
Pulmonary Embolism (PE)
Completeness of excision
Endoscopic excision only
Multidisciplinary review
Medical Oncology (MO) referral
MO FSA
MO FSA date
Offered chemotherapy 
Chemotherapy regimen
Chemotherapy start and stop dates
Duration of chemotherapy
Stopped chemotherapy early
Reason for stopping chemotherapy
Radiation Oncology (RO) referral
RO FSA
RO FSA date
Offered radiotherapy 
Radiotherapy treatment regimen
Radiotherapy start and stop dates
Completeness of radiotherapy treatment
Incomplete radiotherapy due to toxicity
Presentation
Method of referral
Date of referral
Evidence of obstruction
Date of First Specialist Assessment (FSA)
FSA Department
Emergency presentation to secondary care
Staging
Initial diagnosis method
Date of initial diagnosis
Site of primary tumour
Tumour sidedness
Synoptic pathology report
Post-op T stage
Post-op N stage
Post-op M stage
No. lymph nodes examined
No. positive lymph nodes
Lymphovascular invasion 
Tumour differentiation
Distance of tumour to circumferential margin
Mesorectal quality
Computed Tomography (CT) of abdomen/pelvis 
CT chest
Colonoscopy
Completeness of pre-op colonoscopy
Sigmoidoscopy
Pre-operative stage
Post-operative stage
Stage at start of adjuvant therapy
Completeness of staging
Follow up
Date of follow-up visit
Department of follow-up visit
Progressive Disease Outcome
Site of first progressive disease
Date of diagnosis of first progressive disease
Method of diagnosis
Treatment of progressive disease yes/no
Surgical treatment detail
Chemotherapy treatment detail
Radiotherapy treatment 
Interventional radiology treatment detail
Reversal of stoma
Diagnosis of metachronous tumour
Diagnosis of new primary disease
Date last seen
For those who died:
 - cause of death
 - date of death 
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cross checks of related variables.  
Queries generated by these checks were 
forwarded to the regional data managers or 
to the project manager for resolution. Free 
text fields on the database were coded by 
an investigator or advisor with the appro-
priate expertise. Final cohort membership 
was determined based on the PIPER date of 
diagnosis post final data cleaning. 
Statistical methods: Analyses are strat-
ified by cancer site (colon vs rectal). The 
demographic and clinical characteristics 
of the cohort are described using appro-
priate numerical summary measures and 
graphs. Comparisons between groups 
(rurality, ethnicity and deprivation) in terms 
of presentation, staging, treatment and 
management (Table 1) are adjusted for: age, 
stage, co-morbidity and other prior factors 
(as appropriate), using generalised linear 
models.29 Specific analyses are carried out 
for comparisons by ethnicity, using data 
for patients diagnosed in 2006–2009, using 
sampling weights to allow for the sampling 
of nMnP patients in the years 2006 and 2009. 
For each site and stage, where numbers 
permit, statistical models (including Cox 
regression and competing risk models) 
are used to explore the factors that may 
determine differences in patient outcome 
(cause-specific survival and overall survival) 
by rurality, ethnicity and social deprivation.
Sample size justification: Sample size 
calculations were done for the main PIPER 
cohort, years 2007 and 2008 (n=4,950), as 
some analyses are limited to this group. 
Of the 3,630 colon cancer patients and the 
1,165 rectal cancer patients with known 
rurality in the main cohort, 26% lived 
in rural areas at diagnosis. To detect a 
difference in proportions meeting KPIs 
between urban and rural patients of 0.11 at 
the 0.05 level (2-sided) with a power of 80%, 
we would need 840 patients. Thus we have 
at least 80% power to detect differences in 
KPIs as small as 0.11 for the colon cancer 
group, the rectal cancer group, for stage II 
and III colon cancer patients (n=1,016 and 
916 respectively), the group with non-met-
astatic rectal cancer (n=912) and the group 
with metastatic colorectal cancer (n=1,098). 
For evaluation of care for Māori and Pacific 
patients we use the extended PIPER cohort. 
The total number of Māori patients, with a 
known diagnosis, over the four years was 
445. Of these, 308 had a diagnosis of colon 
cancer (including recto-sigmoid) and 137 
rectal cancer. With these numbers we have 
80% power to detect differences in propor-
tions greater than 0.17 between Māori 
and nMnP at the 0.05 level in the overall 
comparisons and stage-specific compar-
isons. There were a total of 133 Pacific 
patients with a known diagnosis; 78 with 
colon cancer and 55 with rectal cancer. The 
smaller number of Pacific patients (even 
using total ethnicity rather than prioritsed 
ethnicity), means we have 80% power to 
detect differences greater than 0.3. 
Project approval and conduct: Ethical 
approval for this project was granted 
by the Multi-Region Ethics Committee 
(reference number MEC/12/EXP/022). 
Approval was granted for data to be 
collected without individual patient 
consent. The project was overseen by the 
PIPER Study Management Group. 
Results
There were 5,612 diagnoses of CRC regis-
tered on the NZCR during the years 2007 and 
2008. In the extended cohort, there were an 
additional 244 Māori patients, 99 Pacific and 
432 nMnP patients. This gave 6,387 poten-
tially eligible cases for review. Of these 6,387 
patients, 5,610 (88%) were determined to 
be eligible for the PIPER study. Exclusions 
included: non-adenocarcinoma morphology 
(n=172; 2.7%); no evidence of CRC found in 
the available clinical records (151; 2.4%); 
diagnosed outside study years (147; 2.3%); 
non-colorectal primary (120; 1.9%); no clinical 
records available on the patient (67; 1%); 
diagnosed or treated outside New Zealand 
(58; 0.9%); recurrent disease (47; 0.7%); not a 
New Zealand resident (10; 0.2%) and clinical 
diagnosis only (ie no pathology or radiology 
to confirm diagnosis (5; 0.1%)). Review of 
eligibility by patient variables demonstrated 
little variation by rurality and deprivation 
status, however Māori and Pacific patients 
had a greater proportion ineligible due to 
non-adenocarcinoma (6% for Māori and 7% 
for Pacific compared to 2% in nMnP). 
Comparison of site of primary cancer 
collected for the PIPER project compared 
to that recorded on the NZCR showed 
reasonable consistency for colon cancer; 
of the 3,695 patients with colon cancer 
according to the PIPER notes review, 3,565 
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(97%) were classified as colon cancer on 
the NZCR (Table 2). Greater variability was 
seen with rectal cancer; of the 1,385 clas-
sified as rectal cancers in PIPER, only 1,226 
(89%) were classified as rectal cancer on the 
NZCR. The remaining 11% of cases classified 
as rectal in PIPER were recorded on the 
registry as being located in the rectosigmoid 
(6%) or in the colon (5%). The discrepancy 
is due in part to differences in the source of 
information (PIPER used the operation note 
where this was available, as opposed to the 
pathology report which is used by the NZCR) 
and in part to the difficulty in classifying 
cancers near the rectosigmoid junction. 
Tumours classified as being located in the 
recto-sigmoid in PIPER showed the greatest 
variability with 208/466 (45%) also being 
classified as recto-sigmoid by the NZCR.
Characteristics of the 
PIPER patient cohort
The number of cases included for each 
year, based on date of diagnosis, by site of 
primary tumour and prioritised ethnicity is 
given in Table 3, illustrating the sampling 
for the extended cohort (years 2006 and 
2009). Across the four years, the estimated 
percentages of patients whose tumour 
site was the colon, rectum and recto-
sigmoid junction were 66%, 25% and 7% 
respectively. For 2%, the tumour site was 
unknown. These percentages are weighted 
back to the population according to the 
sampling weights. Table 4 presents the 
numbers and percentages of patients by 
demographic characteristics for colon, 
rectal and recto-sigmoid cancers (also 
weighted back to the population). Overall 
5% of the CRC population were Māori and 
1% Pacific, reflecting the lower CRC inci-
dence among Māori and Pacific.
Discussion
The PIPER project has generated a data 
set of over 960,000 data points for 5,613 
patients diagnosed with CRC in New 
Zealand. Cases were identified from the 
mandatory population-based NZCR. We 
observed a reasonable level of accuracy 
with respect to CRC diagnosis on the NZCR; 
2% of those coded as ICD-10-AM codes 
C18-20 were found to have a non-colorectal 
primary on hand search of the medical 
record. For a further 2.4% we found 
no evidence of cancer in their medical 
records; however these cases included 
people diagnosed and managed conserva-
tively outside the secondary care setting, 
or patients who were managed solely 
within the private sector but for whom no 
private sector records could be accessed. 
Secure storage, filing and access to retired 
practitioners’ records in the private sector 
were found to vary greatly between indi-
viduals, and complicated data retrieval. 
We confirmed that the majority of cases of 
C18-C20 recorded on the NZCR are adeno-
carcinoma morphology (97%).
Further work is planned to compare the 
data held by the NZCR and the PIPER data. 
The classification of primary site as colon 
or rectum varied between the registry and 
the PIPER data set, particularly for rectal 
and recto-sigmoid cancers. This is likely to 
be due to differing definitions; in PIPER we 
classified site of primary disease by prior-
itisation from operation note, followed by 
pathological report for surgical specimen, 
followed by other pathological report 
(eg, biopsy post-colonoscopy), followed 
by colonoscopy report, and followed by 
other as written in medical record. The 
NZCR appears to use the first pathological 
diagnosis that would, for many cases, arise 
Table 2: Site of primary tumour as found in the PIPER Project compared to that recorded on the NZCR.
PIPER site of cancer
NZCR site of 
cancer
Colon Rectum Recto-sigmoid Unknown
N % N % N % N % Total %
Colon 3,565 96.5 72 5.2 118 25.3 56 87.5 3,811 67.9
Rectum 54 1.5 1,226 88.5 140 30.0 6 9.4 1,426 25.4
Recto-sigmoid 76 2.1 87 6.3 208 44.6 2 3.1 373 6.6
Total 3,695 100.0 1,385 100.0 466 100.0 64 100.0 5,610 100.0
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Table 3: Numbers of patients with colorectal cancer included in the PIPER cohort 
by year of pathological diagnosis.
Year of diagnosis
Site Prioritised Ethnicity 2006*
N
2007
N
2008
N
2009*
N
Total 
N
Colon Māori 64 60 60 72 256
Pacific 21 9 18 18 66
nonMāori - nonPacific 101 1,531 1,576 109 3,317
Unknown 0 29 24 3 56
Rectum Māori 34 39 22 42 137
Pacific 12 10 13 20 55
nonMāori - nonPacific 41 566 518 39 1,164
Unknown 1 11 16 1 29
Recto-sig-
moid
Māori 14 14 10 14 52
Pacific 3 0 7 2 12
nonMāori - nonPacific 12 178 189 14 393
Unknown 0 6 2 1 9
Unknown Māori 4 2 2 3 11
Pacific 1 1 0 0 2
nonMāori - nonPacific 0 18 16 12 46
Unknown 0 3 0 2 5
All Māori 116 115 94 131 456
Pacific 37 20 38 40 135
nonMāori - nonPacific 154 2,293 2,299 164 4,920
Unknown 1 49 42 7 99
Total 308 2,477 2,473 352 5,610
*The cohort was extended to include patients diagnosed in 2006 and 2009 to provide more 
information on Māori and Pacific patients. All Māori and all Pacific patients were included, 
and a random sample of nonMāori-nonPacific patients.
from the colonoscopy pathology report. 
During data collection we noted regular 
variation between the site of disease as 
documented across multiple documents, 
eg, operation note versus discharge 
summary versus colonoscopy report; and 
between pathology report of endoscopic 
biopsy specimen and surgical specimen. 
For 1% of the study population, the site of 
primary disease was not able to be defined 
below the level of colorectal. This included 
patients for whom data were unable to 
be accessed, for example portions of the 
medical record (eg, volumes) were missing 
or access to private sector data were not 
approved by a private physician. 
Data were collected from source docu-
mentation in both public and private 
medical records. While retrospective 
review presents challenges and limita-
tions with respect to consistency and 
accuracy of data collection, we minimised 
the impact of this through: clear documen-
tation of field definitions and source data; 
training, monitoring and regular meetings 
of project-specific data managers; and 
review of all available records and data 
sets for individual cases. Selection of the 
study cohort was considered to provide a 
balance between the age of the data and the 
ability to include a minimum of five-year 
follow-up for outcome assessment. There 
ARTICLE
33 NZMJ 19 August 2016, Vol 129 No 1440ISSN 1175-8716                 © NZMA
www.nzma.org.nz/journal
Table 4: Demographic characteristics of the patients included in the PIPER cohort (so include patients in both the main and extension 
cohorts).
Colon Rectum Recto-sig-
moid
Un-
known
Total
N %† N %† N %† N N %†
Gender Female 1,944 52.28 521 33.92 194 34.64 31 2,690 46.63
Male 1,751 47.72 864 66.08 272 65.36 33 2,920 53.37
Age at diagnosis <40 66 1.24 29 1.98 11 1.50 0 106 1.42
40–49 145 3.75 90 8.06 23 5.44 0 258 4.87
50–59 368 10.84 226 16.21 66 10.60 13 673 12.45
60–69 870 21.17 399 26.82 137 28.42 16 1,422 23.19
70–79 1,261 36.39 399 31.49 145 35.48 15 1,820 34.89
>=80 985 26.62 242 15.43 84 18.56 20 1,331 23.18
Unknown 
Age
3 0 0 0 3
Prioritised Ethnicity Māori 256 3.87 137 5.62 52 7.28 11 456 4.60
Pacific 66 1.00 55 2.26 12 1.68 2 135 1.36
non Māori 
- nonPa-
cific
3,317 95.13 1,164 92.13 393 91.04 46 4,920 94.04
Unknown 
Ethnicity
56 29 9 5 99
Rurality of residence at time of 
diagnosis
Urban 2,650 72.64 992 71.04 338 74.10 19 3,999 72.33
Rural 954 27.36 357 28.96 120 25.90 9 1,440 27.67
Unknown 
Rural
91 36 8 36 171
New Zealand Deprivation Index 
of residence at time of diagnosis
1–2 714 22.25 262 15.58 83 19.92 3 1,062 20.36
3–4 713 19.55 268 19.54 87 17.88 8 1,076 19.45
5–6 801 19.69 278 22.92 105 19.86 6 1,190 20.52
7–8 744 24.65 278 23.88 92 21.56 4 1,118 24.20
9–10 612 13.87 256 18.08 88 20.77 7 963 15.47
Unknown 
Dep
111 43 11 36 201
Total Total 3,695 100.0 1,385 100.0 466 100.0 64 5,610 100.0
†Percentages have been calculated weighted back to the population values using the sampling weights, to account for incomplete sampling of nMnP in 
2006 and 2009. Percentages do not include unknowns.
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have been limited changes to treatment 
practice of CRC in New Zealand in the 
interval between the cohort timeframe and 
the present day. 
The data collected in PIPER will also 
allow us to investigate issues such as the 
group of data fields that were unable to be 
captured retrospectively from the medical 
records. We believe that this and on-going 
findings from the data set will highlight the 
need for a method of routine/prospective 
data collection across both the public and 
private sectors if we wish to continue to 
monitor quality of care provided to patients 
with CRC in New Zealand.
Conclusions
The PIPER Project has provided a popu-
lation level, comprehensive data set 
detailing the diagnosis and management of 
CRC in New Zealand, a disease with signif-
icant disparities in outcome for patients in 
New Zealand. It provides a rich resource 
for studying the factors which may explain 
these disparities and further analyses of the 
collected data are currently underway.
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